Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) shares added more than 75% on Monday after positive results from a trial of the company’s coronary heart disease (CHD) test PrecisionCHD were published in the Journal of the American Heart Association.
The company noted that PrecisionCHD is a non-invasive and more accessible alternative to current CHD diagnosis tools being in the form of a blood test that uses AI and personalized genetic and epigenetic information to sensitively detect the presence of CHD.
The published study, a collaboration between the company and Intermountain Healthcare and the University of Iowa Hospitals and Clinics, described the development and validation of the PrecisionCHD test in three cohorts made up of more than 2,500 patients.
Cardio Diagnostics highlighted that by using the input from six methylation-sensitive digital PCR (MSdPCR), the tool can provide clinicians with personalized insights into each patient's CHD presentation.
"This study marks a significant step forward in CHD diagnosis, leveraging the synergies of genetics, epigenetics, and AI to offer a highly sensitive, efficient, scalable and personalized approach for CHD care," Cardio Diagnostics CEO Meesha Dogan said in a statement.
Cardio Diagnostics chief medical officer Robert Philibert added that “this is a game changer for personalized cardiovascular care” and “unlike other methods of CHD testing, there is no exposure of patients to ionizing radiation or potentially kidney damaging contrast dye."
“What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans,” Philibert said.
Cardio Diagnostics shares were up 75.8% at US$1.72 shortly before noon on Monday.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie